Alembic Pharmaceuticals gets USFDA final approval for Dabigatran Etexilate capsules
Dabigatran Etexilate Capsules are indicated for reduction of risk of stroke and systemic embolism in non-valvular atrial fibrillation in adult patients
Dabigatran Etexilate Capsules are indicated for reduction of risk of stroke and systemic embolism in non-valvular atrial fibrillation in adult patients
Cipla had earlier invested € 15 million in Ethris in 2022
The USFDA has issued 15 observations pursuant to the completion of audit. JHSGP will submit an action plan on the observations
Abdel has held leadership positions at Bayer, Merck, Catalent, Lonza, and KBI Biopharma,
Jubilant's Radiopharma Business to expand positron emission tomography radiopharmacy network
As on 31st March 2024, Jubilant Pharmova Limited reported Gross Debt at Rs. 3,414 crore
Fischer MVL envisages to offer a diverse portfolio of diagnostic solutions
Sapala has a strong customer base including innovator Pharma, CDMOs & diagnostic companies
The primary endpoint in the final analysis was assessed by change in the North Star Ambulatory Assessment at one year after treatment
SYNERGY-NASH results were presented at the European Association for the Study of the Liver Congress 2024 and simultaneously published in The New England Journal of Medicine
Subscribe To Our Newsletter & Stay Updated